Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dibromodulcitol + mitomycin c + vinblastine
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of dibromodulcitol, mitomycin C, and vinblastine. Dibromodulcitol is an alkylating agent that interferes with DNA replication and transcription. Mitomycin C is an antitumor antibiotic that acts as a bioreductive alkylating agent, cross-linking DNA and inhibiting DNA synthesis. Vinblastine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, arresting cell division at metaphase. The DMV regimen has been studied primarily for advanced breast cancer, showing moderate efficacy with manageable toxicity profiles[1][5].
- Other names
- DMV chemotherapy
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dibromodulcitol + mitomycin c + vinblastine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dibromodulcitol + mitomycin c + vinblastine.